Yıl: 2010 Cilt: 18 Sayı: 4 Sayfa Aralığı: 253 - 262 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Kuru tip yaşa bağlı makula dejeneresansı tedavisi

Öz:
Yaşa bağlı makula dejeneresansı (YBMD) dünyada yasal körlük nedenleri içinde 3. sırada yer almaktadır. Halen dünyada 30-50 milyon kişide var olduğu bildirilen YBMD’lı hasta sayısının gelecek dekatta iki katına çıkması beklenmektedir. YBMD’nın değiştirilebilir risk faktörleri olan sigara, beslenme, obesite, sistemik hastalıklar ve çevresel faktörler ile ilişkisinin iyi bilinmesi, hastalıktan korunma ve ilerlemesini azaltma yönünden önem taşımaktadır. Ayrıca gerekli besinlerin diyetle alınamaması da risk faktörlerinden biridir. Diyetle alınması gereken Vitamin C, D, E, selenyum, çinko, bakır, magnezyum eser mineralleri ile a ve ß karoten, kriptoksantin, lutein ve zeaksantin gibi antioksidanların eksikliği YBMD patogenezinde rol oynamaktadır. YBMD’nın önlenmesi ve ilerlemesinin yavaşlatılması için risk faktörleri de göz önüne bulundurularak sağlıklı bir yaşam biçimi sürdürmek, özellikle 55 yaşın üzerindeki sağlıklı bireylere direkt güneş ışığından korunma, sigarasız yaşam, düzenli egzersiz, kilo, tansiyon ve kolesterol kontrolü, yağı ve şekeri azaltıp, koyu yeşil yapraklı sebzeler, ceviz ve meyve yanı sıra haftada 1-2 kez balık tüketmeleri önerilmelidir. Ancak erken evre YBMD saptandığında 10 mg/gün lutein ve 500-1000 mg/gün omega 3 alımı uygun görülürken, bir gözde ileri evre YBMD varlığında AREDS çalışmalarında belirlenen yoğun antioksidan desteği gündeme gelebilir. Antioksidan, vitamin ve mineral desteği en azından diğer gözü korumak için yararlı olmasına rağmen destek tedavisinin de yan etkileri olduğu unutulmamalıdır. YBMD tedavisi için drusen üzerine veya grid şeklinde lazer, reoferez, kapsül içi minyatür teleskop ve makula translokasyonu tedavileri denenmiş, ancak yeterli başarı elde edilememiştir. Bu çalışmaların yanı sıra patofizyoloji, immünoloji ve genetik alanında yeni gelişmelere paralel yeni tedavi seçenekleri gündeme gelecektir.
Anahtar Kelime:

Konular: Göz Hastalıkları

Treatment of dry age-related macular degeneration

Öz:
Age related macular degeneration (ARMD) is the third most common reason for legally blindness in the world. It is known that it currently exists between 30 and 50 million people around the world and is estimated that will have doubled by the end of the coming decade. It is important to know the relation between changeable risk factors of ARMD, which are smoking, diet, obesity, systemic diseases and environmental factors and the disease is important in terms of preventing and decreasing the progression in the disease. Another risk factor is the fact that the necessary dietary supplements can not be consumed in certain diets. Lack of antioxidants like lutein, zeaxanthin, cryptoxanthin, alpha-carotene, and beta-carotene together with vitamins C, D, E, and zinc, copper, selenium, magnesium trace minerals play a role in ARMD pathogenesis. In order to prevent or decrease the progression in ARMD and to live a healthy life, people especially over 55 years should be suggested to keep away from sunlight, a life without smoking, regular physical activity, controlled weight, blood pressure and cholesterol, decreased fat and sugar consumption and cunsumption of green vegetables, walnut and fruit, together with fish once or twice a week. If ARMD is diagnosed in an early stage, 10mg/day lutein and 500-1000 mg/day omega-3 intake is suitable. If there is advanced stage ARMD in one eye, intense antioxidan supplement may be thought about as mentioned in AREDS studies. Antioxidant, vitamin and mineral supplements are good in terms of protecting the other eye, but it should be kept in mind that these treatments also have their side effects. Laser treatment in eyes with drusen, Rheopheresis, Implantable miniature telescope and macular translocation have been tried for ARMD treatment; however, have not proved effective. Research on Glatiramer Acetate (Vaccination With Copaxone), Fenretinide, Eculizumab (Soliris), ARC1905 (Anti-C5 Aptamer), RN6G, Photobiomodulation, OT-551 and AL-8309B Antioxidant Eye Drops, Sirolimus (Rapamycin), Encapsulated Cell Technology Implant (Cilier Nörotrofik Faktör) ve RPE Transplantation (Retinal Replacement Therapy) is still being conducted. Along with these, there will be new treatment alternatives together with the developments related to pathophysiology, immunology and genetic sciences.
Anahtar Kelime:

Konular: Göz Hastalıkları
Belge Türü: Makale Makale Türü: Diğer Erişim Türü: Bibliyografik
  • # Klein R.: Epidemiology of age-related macular degeneration. In: Penfold PL, Provis JM eds: Macular Degeneration. Germany, Springer-Verlag Berlin Heidelberg, 2005;5:79-101.
  • # Bulletin of the World Health Organization in November, 2004:82,11
  • # Akbatur HH. Şengün A.: Yaşa bağlı makula dejenerasyonu. Proplast, Ankara. 1998;1-40.
  • # Boldt HC, Bressler SB, Fine SL, et al.: Age-related macular degeneration. Curr Opin Ophthalmol. 1990;1:247-257.
  • # Age-Related Eye Disease Study Research Group: Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology, 2000;107:2224- 2232.
  • # Leibowitz HM, Krueger DE, Maunder LR, et al.: The Framingham Eye Study Monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol. 1980;24:335-610.
  • # Bressler NM, Bressler SB, West SK, et al.: The grading and prevalence of macular degeneration in Chesapeake Bay watermen. Arch Ophthalmol. 1989;107:847-852.
  • # Klein R, Rowland M, Haris M.: Third National Health and Nutrition Examination Survey. Racial/ethnic differences in age-related maculopathy. Ophthalmology. 1995;102:371-381.
  • # Bürümcek EY.: Yaşa Bağlı Makula Dejeneresansında Risk Faktörleri. 28. Ulusal Oftalmoloji Kursu; Retina “Güncel Tanı ve Tedavi”. Ankara-Türkiye, 11-13 Nisan 2008:23-28.
  • # Seddon JM, Chen CA.: Epidemiology of age-related macular degeneration. Ed. Ryan SJ, In Retina, 4th Ed., Vol 2, Macular Disease, Philadelphia: Mosby Co. 2006;58:1017-1027.
  • # Ergin MH, Koçak N.: Yaşa bağlı makula dejeneresansında epidemiyoloji ve etyopatogenez. Türkiye Klinikleri J Surg Med Sci. 2006;41:1-6.
  • # Eong KG.: Risk Factors for Age-Related Macular Degeneration and Choroidal Neovascularization.In: Lim JI, ed. Age related macular degeneration. Informa Healthcare, New York. 2008;47-86.
  • # Anderson DH, Mullins RF, Hageman GS, et al.: A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002;134:411-431.
  • # Hyman LG, Lilienfeld AM, Ferris FLI, et al.: Senile macular degeneration: a case-control study. Am J Epidemiol. 1983; 118:213- 227.
  • # Bhagat N.: Non-exudative Age-related Macular Degeneration. In: Lim JI, ed. Age related macular degeneration. Informa Healthcare, New York. 2008;97-109.
  • # Seddon JM, George S, Rosner B, et al.: Progression of age-related macular degeneration: prospective assessment of C- reactive protein, interleukin- 6, and other cardiovascular biomarkers. Arch Ophthalmol. 2005;123:774-782.
  • # Obisesan TO, Hirsch R, Kosoko O, et al.: Moderate wine consumption is associated with decreased odds of developing agerelated macular degeneration in NHANES-1. J Am Geriatr Soc. 1998;46:1-7.
  • # Cousins SW, Marin-Castaño ME, Espinosa-Heidmann DG, et al.: Female gender, estrogen loss, and Sub-RPE deposit formation in aged mice. Invest Ophthalmol Vis Sci. 2003;44:1221-1229.
  • # Age-Related Eye Disease Study Research Group. A randomized, placebo controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8 Arch Ophthalmol. 2001;119:1417-1436.
  • # Richter S, Stiles W, Statkute L, et al.: Double masked, placebo controlled randomized trial of lutein and antioxidant supplementation in the prevention of atrophic age related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry. 2004;216-230.
  • # Nolan JM, Stack J, O’ Donovan O, et al.: Risk factors for age related maculopahty are associated with a relative lack of macular pigment. Exp Eye Res. 2007;84:61-74.
  • # SanGiovanni JP, Chew EY, Clemons TE, et al.: Age-Related Eye Disease Study Research Group: The relationship of dietary carotenoid and Vitamin A, E and C intake with Age-Related Macular Degeneration in a case-control study. AREDS Report No.22. Arch Ophthalmol. 2007;125:1225-1232.
  • # Tan JS, WANG jj, Flood V, et al.: the Blue Mountains Eye Study: Dietary antioxidants and the long-term incidence of age-related macular degeneration. Ophthalmology. 2008;115:334-341.
  • # Trieschmann, M, Beatty S, Nolan JM et al.: Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin:the LUNA study. Exp Eye Res. 2007;84:718-28.
  • # Seddon JM, Ajani UA, Sperduto RD, et al.: Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA 1994; 272:1413-1420.
  • # Bressler NM, Bressler, SB, Congdon NG, et al.: Age-Related Eye Disease Study Research Group: Potential public health impact of Age-Related Eye Disease Study results: AREDS report no11. Arch Ophthalmol. 2003;121:1621-1624.
  • # Tan JS, Wang JJ, Flood V, et al.: Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology. 2008;115:334-341.
  • # Taylor HR,Tikellis G, Robman LD, et al.: Vitamin E supplementation and macular degeneration: VECAT study -randomized controlled trial. BMJ. 2002;11:325.
  • # Menteş J.: Yaşa Bağlı Makula Dejeneresansının Tedavisi.Türk Oftalmoloji Derneği Eğitim Yayınları No:19; Tıbbi Retina. Ankara -Türkiye 2009;85-87.
  • # Parekh N, Chappell RJ, Millen AE, et al.: Association between vitamin D and age-related macular degeneration in the third National Health and Nutrition Examination Survey.1988-1994. Arch Ophthalmol 2007;125:661-669.
  • # Prada AS.: Zinc: role in immunity, oxidative stress and chronic inflammation. Curr Opin Clin Nutr Metab Care. 2009;12:646-652.
  • # Ferris FL, Davis MD, Clemons TE, et al.: Age-Related Eye Disease Study (AREDS) Research Group. A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol. 2005;123:1570-1574.
  • # Seddon J, Cote J, Rosner B.: Progression of age related macular degeneration: association with dietary fat, trans-unsaturated fat, nuts, and fish intake. Arch Ophthalmol. 2003;121:1728-1737.
  • # SanGiovanni JP, Chew EY, Clemons TE, et al.: Age-Related Eye Disease Study Research Group: The Relationship of Dietary Lipid Intake and Age-Related Macular Degeneration in a Case-Control Study :AREDS Report No. 20 Arch Ophthalmol. 2007;125:671- 679.
  • # Smith W, Mitchell P, Leeder SR.: Dietary fat and fish intake and age-related maculopathy. The Blue Mountains Eye Study.Arch Ophthalmol. 2000;118:401-404.
  • # Goodrow EF, Wilson TA, Houde SC, et al.: Consumption of one egg per day increases serum lutein and zeaxanthin concentrations in older adults without altering serum lipid and lipoprotein cholesterol concentrations. J Nutrition. 2006;136:2519-2524.
  • # Rehak M, Fric E, Wiedemann P.: Lutein and antioxidants in the prevention of age-related macular degeneration [Review]. Ophthalmologe. 2008;105:37.
  • # Olk RJ, Friberg TR, Stickney KL et al.: Therapeutic benefits of infrared (810-nm) diode laser macular grid photocoagulation in prophylactic treatment of nonexudative age-related macular degeneration: two-year results of a randomized pilot study. Ophthalmology. 1999;106:2082-2090.
  • # Ho AC.: Laser treatment in eyes with drusen. Review. Curr Opin Ophthalmol. 1999;10:204-208.
  • # Ho AC, Maguire MG, Yoken J et al.: Choroidal Neovascularization Prevention Trial Research Group: Laser-induced drusen reduction improves visual function at 1 year. Ophthalmology. 1999;106:1367-1373.
  • # Rodanant N, Friberg TR, Cheng L, et al.: Predictors of drusen reduction after subthreshold infrared (810 nm) diode laser macular grid photocoagulation for nonexudative age-related macular degeneration.Am J Ophthalmol. 2002;134:577-585.
  • # Pulido JS.: Multicenter Investigation of Rheopheresis for AMD (MIRA-1) Study Group. Multicenter prospective, randomized, double- masked, placebo-controlled study of Rheopheresis to treat nonexudative age-related macular degeneration: interim analysis. Trans Am Ophthalmol Soc. 2002;100:85-106.
  • # Hudson HL, Lane SS, Heier JS; et al.: Implantable miniature telescope for the treatment of visual acuity loss resulting from endstage age-related macular degeneration: 1-year results. Ophthalmology. 2006;113:1987-2001.
  • # Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-Related Macular Degeneration. Clinicaltrials.gov, identifier: NCT00541333.
  • # Copaxone in Age Related Macular Degeneration. Clinicaltrials. gov, identifier: NCT00466076.
  • # Landa G, Butovsky O, Shoshani J, et al.: Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry agerelated macular degeneration. Curr Eye Res. 2008;33:1011- 1013.
  • # Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration ClinicalTrials. gov, identifier: NCT00429936.
  • # Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD) (COMPLETE) ClinicalTrials. gov, identifier: NCT00935883.
  • # A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration ClinicalTrials.gov, identifier: NCT00950638.
  • # Safety And Tolerability Study Of RN6G In Patients With Dry, Age- Related Macular Degeneration. ClinicalTrials.gov, identifier: NCT00877032.
  • # Ding JD, Lin J, Mace BE, et al.: Targeting age-related macular degeneration with Alzheimer’s disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model. Vision Res. 2008;48: 339-345.
  • # Toronto and Oak Ridge Photobiomodulation Study for Dry Age Related Macular Degeneration (TORPA) ClinicalTrials.gov, identifier: NCT00940407.
  • # The OMEGA Study: Use of Eye Drops to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration (Dry AMD) ClinicalTrials.gov, identifier: NCT00485394.
  • # OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration. ClinicalTrials.gov, identifier: NCT00306488.
  • # Geographic Atrophy Treatment Evaluation (GATE) ClinicalTrials. gov, identifier: NCT00890097.
  • # Sirolimus to Treat Geographic Atrophy Associated With Age- Related Macular Degeneration. ClinicalTrials.gov, identifier: NCT00766649.
  • # A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular Degeneration ClinicalTrials.gov Identifier: NCT00447954.
APA yazar z, ZIRIĞ H (2010). Kuru tip yaşa bağlı makula dejeneresansı tedavisi. , 253 - 262.
Chicago yazar zeliha,ZIRIĞ Halil İbrahim Kuru tip yaşa bağlı makula dejeneresansı tedavisi. (2010): 253 - 262.
MLA yazar zeliha,ZIRIĞ Halil İbrahim Kuru tip yaşa bağlı makula dejeneresansı tedavisi. , 2010, ss.253 - 262.
AMA yazar z,ZIRIĞ H Kuru tip yaşa bağlı makula dejeneresansı tedavisi. . 2010; 253 - 262.
Vancouver yazar z,ZIRIĞ H Kuru tip yaşa bağlı makula dejeneresansı tedavisi. . 2010; 253 - 262.
IEEE yazar z,ZIRIĞ H "Kuru tip yaşa bağlı makula dejeneresansı tedavisi." , ss.253 - 262, 2010.
ISNAD yazar, zeliha - ZIRIĞ, Halil İbrahim. "Kuru tip yaşa bağlı makula dejeneresansı tedavisi". (2010), 253-262.
APA yazar z, ZIRIĞ H (2010). Kuru tip yaşa bağlı makula dejeneresansı tedavisi. Retina-Vitreus, 18(4), 253 - 262.
Chicago yazar zeliha,ZIRIĞ Halil İbrahim Kuru tip yaşa bağlı makula dejeneresansı tedavisi. Retina-Vitreus 18, no.4 (2010): 253 - 262.
MLA yazar zeliha,ZIRIĞ Halil İbrahim Kuru tip yaşa bağlı makula dejeneresansı tedavisi. Retina-Vitreus, vol.18, no.4, 2010, ss.253 - 262.
AMA yazar z,ZIRIĞ H Kuru tip yaşa bağlı makula dejeneresansı tedavisi. Retina-Vitreus. 2010; 18(4): 253 - 262.
Vancouver yazar z,ZIRIĞ H Kuru tip yaşa bağlı makula dejeneresansı tedavisi. Retina-Vitreus. 2010; 18(4): 253 - 262.
IEEE yazar z,ZIRIĞ H "Kuru tip yaşa bağlı makula dejeneresansı tedavisi." Retina-Vitreus, 18, ss.253 - 262, 2010.
ISNAD yazar, zeliha - ZIRIĞ, Halil İbrahim. "Kuru tip yaşa bağlı makula dejeneresansı tedavisi". Retina-Vitreus 18/4 (2010), 253-262.